"İstanbul Üniversitesi İstanbul Tıp Fakültesi Türkiye'nin sağlık eğitiminde öncü üniversitesi olarak Evrensel standartlara sahip nitelikli hekimler ve bilim insanları yetiştiren, ülkemize ve insanlığa yararlı bilgi üreten, kaliteli sağlık hizmeti sunan ve bu işlevleri etkin şekilde koordine eden öncü bir kurum olmak misyonuyla eğitim vermektedir."

During the past decade, Istanbul University Istanbul Medical Faculty conducted 124 clinical trials. In the 10-year time frame, 124 clinical trials started and 28 clinical trials were completed, i.e. on average, 22.6% percent of trials that started reached the finish line to date. In the past 5 years, 68 clinical trials started and 20 clinical trials were completed. i.e. 29.4% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Istanbul University Istanbul Medical Faculty" #1 sponsor was "Istanbul University" with 38 trials, followed by "Janssen Research & Development, LLC" with 15 trials sponsored, "Hoffmann-La Roche" with 14 trials sponsored, "Bayer" with 7 trials sponsored and "Pfizer" with 7 trials sponsored. Other sponsors include 67 different institutions and companies that sponsored additional 52 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Istanbul University Istanbul Medical Faculty" #1 collaborator was "Istanbul University" with 3 trials as a collaborator, "Acibadem Fulya Hospital" with 2 trials as a collaborator, "Atea Pharmaceuticals, Inc." with 2 trials as a collaborator, "Istanbul University - Cerrahpasa (IUC)" with 2 trials as a collaborator and "Marmara University" with 2 trials as a collaborator. Other collaborators include 36 different institutions and companies that were collaborators in the rest 46 trials.

According to Clinical.Site data, the most researched conditions in "Istanbul University Istanbul Medical Faculty" are "Multiple Myeloma" (6 trials), "Breast Cancer" (5 trials), "COVID-19" (5 trials), "Ulcerative Colitis" (4 trials) and "Cerebral Palsy" (3 trials). Many other conditions were trialed in "Istanbul University Istanbul Medical Faculty" in a lesser frequency.

Most popular intervention types in "Istanbul University Istanbul Medical Faculty" are "Drug" (86 trials), "Procedure" (19 trials), "Other" (18 trials), "Biological" (10 trials) and "Device" (5 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (28 trials), "Dexamethasone" (7 trials), "Bortezomib" (5 trials), "Daratumumab" (5 trials) and "Rituximab" (5 trials). Other intervention names were less common.

The vast majority of trials in "Istanbul University Istanbul Medical Faculty" are 130 trials for "All" genders, 16 trials for "Female" genders and 7 trials for "Male" genders.

Currently, there are NaN active trials in "Istanbul University Istanbul Medical Faculty". undefined are not yet recruiting, 33 are recruiting, 16 are Active, not recruiting, and 2 are Enrolling by invitation. In total, there were 76 completed trials in Istanbul University Istanbul Medical Faculty, undefined suspended trials, and 12 terminated clinical trials to date.

Out of the total trials that were conducted in Istanbul University Istanbul Medical Faculty, 2 "Phase 1" clinical trials were conducted, 19 "Phase 2" clinical trials and 66 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 4 trials, and there were also 34 trials that are defined as “Not Applicable".